Recently, the benefit of combining nivolumab and relatlimab, a new ICI that blocks the lymphocyte-activation gene (LAG-3), has been shown in patients with advanced melanoma (Tawbi et al., 2022). This evidence concerns the gene LAG3 and melanoma.